Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 14/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22744220 | 1.00 | MAP4K4 (0.36) | MAP4K4MAP3K14 | |
| SCHEMBL22744256 | 1.00 | MAP4K4 (0.36) | MAP4K4MAP3K14 | |
| SCHEMBL22744222 | 0.83 | MAP3K14 (0.38) | MAP4K4MAP3K14 | |
| SCHEMBL23870160 | 0.82 | MAP4K4 (0.36) | MAP4K4MAP3K14 | |
| SCHEMBL23870034 | 0.81 | MAP3K14 (0.37) | MAP4K4MAP3K14 | |
| SCHEMBL22744185 | 0.81 | MAP3K14 (0.37) | MAP4K4MAP3K14 | |
| SCHEMBL23869944 | 0.80 | MAP4K4 (0.36) | MAP4K4MAP3K14 | |
| SCHEMBL22715021 | 0.78 | MAP3K14 (0.45) | MAP4K4MAP3K14 | |
| SCHEMBL22716310 | 0.78 | MAP3K14 (0.45) | MAP4K4MAP3K14 | |
| SCHEMBL22715612 | 0.78 | MAP3K14 (0.45) | MAP4K4MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2020239999-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | MAP4K4 104/4885MAP3K14 35/4885 |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | MAP4K4 104/4885MAP3K14 35/4885 |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | NFKBIA, IKBKB, CHUK | MAP4K4 113/4885MAP3K14 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.